IDEXX Laboratories, Inc. $IDXX is Fundsmith Investment Services LTD.’s 5th Largest Position

Fundsmith Investment Services LTD. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 688,357 shares of the company’s stock after selling 156,259 shares during the period. IDEXX Laboratories comprises about 6.9% of Fundsmith Investment Services LTD.’s investment portfolio, making the stock its 5th biggest holding. Fundsmith Investment Services LTD. owned 0.86% of IDEXX Laboratories worth $439,784,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Blalock Williams LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth about $590,000. New York State Common Retirement Fund lifted its holdings in shares of IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after buying an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd lifted its holdings in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after buying an additional 4,909 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after buying an additional 187,967 shares in the last quarter. Finally, Orion Porfolio Solutions LLC increased its holdings in IDEXX Laboratories by 116.6% in the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after buying an additional 5,770 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 0.5%

Shares of IDXX stock opened at $573.82 on Friday. The stock’s 50 day simple moving average is $658.17 and its 200 day simple moving average is $666.52. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market capitalization of $45.69 billion, a price-to-earnings ratio of 43.90, a PEG ratio of 3.47 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company earned $2.53 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on IDXX shares. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Insider Buying and Selling at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last quarter. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.